{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:04:51Z","timestamp":1790773491748,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG051538"],"award-info":[{"award-number":["AG051538"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG065517"],"award-info":[{"award-number":["AG065517"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG051538"],"award-info":[{"award-number":["AG051538"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG065517"],"award-info":[{"award-number":["AG065517"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG051538"],"award-info":[{"award-number":["AG051538"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG065517"],"award-info":[{"award-number":["AG065517"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disease with age as a major risk factor. AD is the most common dementia with abnormal structures, including extracellular senile plaques and intraneuronal neurofibrillary tangles, as key neuropathologic hallmarks. The early feature of AD pathology is degeneration of the locus coeruleus (LC), which is the main source of norepinephrine (NE) supplying various cortical and subcortical areas that are affected in AD. The spread of Tau deposits is first initiated in the LC and is transported in a stepwise manner from the entorhinal cortex to the hippocampus and then to associative regions of the neocortex as the disease progresses. Most recently, we reported that the NE metabolite DOPEGAL activates delta-secretase (AEP, asparagine endopeptidase) and triggers pathological Tau aggregation in the LC, providing molecular insight into why LC neurons are selectively vulnerable to developing early Tau pathology and degenerating later in the disease and how \u03b4-secretase mediates the spread of Tau pathology to the rest of the brain. This review summarizes our current understanding of the crucial role of \u03b4-secretase in driving and spreading AD pathologies by cleaving multiple critical players, including APP and Tau, supporting that blockade of \u03b4-secretase may provide an innovative disease-modifying therapeutic strategy for treating AD.<\/jats:p>","DOI":"10.1038\/s12276-020-00494-7","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:04:04Z","timestamp":1598612644000},"page":"1275-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"52","author":[{"given":"Seong Su","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-8154","authenticated-orcid":false,"given":"Keqiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"494_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature20412","volume":"539","author":"RG Canter","year":"2016","unstructured":"Canter, R. G., Penney, J. & Tsai, L. H. The road to restoring neural circuits for the treatment of Alzheimer\u2019s disease. Nature 539, 187\u2013196 (2016).","journal-title":"Nature"},{"key":"494_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","volume":"483","author":"J Nunan","year":"2000","unstructured":"Nunan, J. & Small, D. H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483, 6\u201310 (2000).","journal-title":"FEBS Lett."},{"key":"494_CR3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/nm.4199","volume":"22","author":"X Zhao","year":"2016","unstructured":"Zhao, X. et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat. Med. 22, 1268\u20131276 (2016).","journal-title":"Nat. Med"},{"key":"494_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.jnen.0000196133.74087.cb","volume":"65","author":"T Arai","year":"2006","unstructured":"Arai, T., Miklossy, J., Klegeris, A., Guo, J. P. & McGeer, P. L. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 65, 19\u201325 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"494_CR5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nat. Med. 20, 1254\u20131262 (2014).","journal-title":"Nat. Med"},{"key":"494_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-170959","volume":"63","author":"JP Quinn","year":"2018","unstructured":"Quinn, J. P., Corbett, N. J., Kellett, K. A. B. & Hooper, N. M. Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers. J. Alzheimers Dis. 63, 13\u201333 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"494_CR7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology 42, 631\u2013639 (1992).","journal-title":"Neurology"},{"key":"494_CR8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos, P. et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology 60, 1495\u20131500 (2003).","journal-title":"Neurology"},{"key":"494_CR9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaneurol.2016.2078","volume":"73","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Evaluation of Tau imaging in staging alzheimer disease and revealing interactions between beta-amyloid and tauopathy. JAMA Neurol. 73, 1070\u20131077 (2016).","journal-title":"JAMA Neurol."},{"key":"494_CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Del Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389\u2013404 (2006).","journal-title":"Acta Neuropathol."},{"key":"494_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"494_CR12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","volume":"88","author":"CM Wischik","year":"2014","unstructured":"Wischik, C. M., Harrington, C. R. & Storey, J. M. Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease. Biochem Pharm. 88, 529\u2013539 (2014).","journal-title":"Biochem Pharm."},{"key":"494_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/alzrt175","volume":"5","author":"T Chalermpalanupap","year":"2013","unstructured":"Chalermpalanupap, T. et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimers Res Ther. 5, 21 (2013).","journal-title":"Alzheimers Res Ther."},{"key":"494_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/jnp.16.3.261","volume":"16","author":"N Herrmann","year":"2004","unstructured":"Herrmann, N., Lanctot, K. L. & Khan, L. R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 16, 261\u2013276 (2004).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"494_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-142682","volume":"46","author":"P Theofilas","year":"2015","unstructured":"Theofilas, P., Dunlop, S., Heinsen, H. & Grinberg, L. T. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimer\u2019s disease pathogenesis. J. Alzheimers Dis. 46, 17\u201334 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"494_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neurobiolaging.2006.02.007","volume":"28","author":"A Grudzien","year":"2007","unstructured":"Grudzien, A. et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer\u2019s disease. Neurobiol. Aging 28, 327\u2013335 (2007).","journal-title":"Neurobiol. Aging"},{"key":"494_CR17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960\u2013969 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"494_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","volume":"121","author":"H Braak","year":"2011","unstructured":"Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer\u2019s disease in individuals under thirty. Acta Neuropathol. 121, 171\u2013181 (2011).","journal-title":"Acta Neuropathol."},{"key":"494_CR19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/WCO.0b013e32835a3432","volume":"25","author":"H Braak","year":"2012","unstructured":"Braak, H. & Del Tredici, K. Where, when, and in what form does sporadic Alzheimer\u2019s disease begin? Curr. Opin. Neurol. 25, 708\u2013714 (2012).","journal-title":"Curr. Opin. Neurol."},{"key":"494_CR20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.22615","volume":"70","author":"M Jucker","year":"2011","unstructured":"Jucker, M. & Walker, L. C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532\u2013540 (2011).","journal-title":"Ann. Neurol."},{"key":"494_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/nan.12387","volume":"43","author":"AJ Ehrenberg","year":"2017","unstructured":"Ehrenberg, A. J. et al. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer\u2019s disease. Neuropathol. Appl Neurobiol. 43, 393\u2013408 (2017).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"494_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2018.01.010","volume":"41","author":"D Weinshenker","year":"2018","unstructured":"Weinshenker, D. Long road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 41, 211\u2013223 (2018).","journal-title":"Trends Neurosci."},{"key":"494_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","volume":"989","author":"WJ Burke","year":"2003","unstructured":"Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R. & Zahm, D. S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson\u2019s disease pathogenesis. Brain Res. 989, 205\u2013213 (2003).","journal-title":"Brain Res."},{"key":"494_CR24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JAD-141062","volume":"44","author":"X Liu","year":"2015","unstructured":"Liu, X., Ye, K. & Weinshenker, D. Norepinephrine protects against amyloid-beta toxicity via TrkB. J. Alzheimers Dis. 44, 251\u2013260 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"494_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0006-8993(97)01488-1","volume":"787","author":"WJ Burke","year":"1998","unstructured":"Burke, W. J., Kristal, B. S., Yu, B. P., Li, S. W. & Lin, T. S. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res. 787, 328\u2013332 (1998).","journal-title":"Brain Res"},{"key":"494_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(01)00120-6","volume":"93","author":"SW Li","year":"2001","unstructured":"Li, S. W., Lin, T. S., Minteer, S. & Burke, W. J. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson\u2019s disease pathogenesis. Brain Res Mol. Brain Res. 93, 1\u20137 (2001).","journal-title":"Brain Res Mol. Brain Res"},{"key":"494_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/abio.1999.4196","volume":"273","author":"WJ Burke","year":"1999","unstructured":"Burke, W. J., Chung, H. D. & Li, S. W. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Anal. Biochem 273, 111\u2013116 (1999).","journal-title":"Anal. Biochem"},{"key":"494_CR28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0006-8993(00)03199-1","volume":"891","author":"WJ Burke","year":"2001","unstructured":"Burke, W. J. et al. Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res. 891, 218\u2013227 (2001).","journal-title":"Brain Res."},{"key":"494_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/pr.59.2.1","volume":"59","author":"SA Marchitti","year":"2007","unstructured":"Marchitti, S. A., Deitrich, R. A. & Vasiliou, V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharm. Rev. 59, 125\u2013150 (2007).","journal-title":"Pharm. Rev."},{"key":"494_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","volume":"115","author":"WJ Burke","year":"2008","unstructured":"Burke, W. J. et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193\u2013203 (2008).","journal-title":"Acta Neuropathol."},{"key":"494_CR31","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","volume":"290","author":"C Follmer","year":"2015","unstructured":"Follmer, C. et al. Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J. Biol. Chem. 290, 27660\u201327679 (2015).","journal-title":"J. Biol. Chem."},{"key":"494_CR32","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1073\/pnas.1713969114","volume":"114","author":"SS Kang","year":"2017","unstructured":"Kang, S. S. et al. TrkB neurotrophic activities are blocked by alpha-synuclein, triggering dopaminergic cell death in Parkinson\u2019s disease. Proc. Natl Acad. Sci. USA 114, 10773\u201310778 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biochi.2015.09.022","volume":"122","author":"E Dall","year":"2016","unstructured":"Dall, E. & Brandstetter, H. Structure and function of legumain in health and disease. Biochimie 122, 126\u2013150 (2016).","journal-title":"Biochimie"},{"key":"494_CR34","doi-asserted-by":"crossref","first-page":"33194","DOI":"10.1074\/jbc.M302742200","volume":"278","author":"K Shirahama-Noda","year":"2003","unstructured":"Shirahama-Noda, K. et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J. Biol. Chem. 278, 33194\u201333199 (2003).","journal-title":"J. Biol. Chem."},{"key":"494_CR35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.molcel.2008.02.017","volume":"29","author":"Z Liu","year":"2008","unstructured":"Liu, Z. et al. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol. Cell 29, 665\u2013678 (2008).","journal-title":"Mol. Cell"},{"key":"494_CR36","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/pmic.201200006","volume":"12","author":"JH Herskowitz","year":"2012","unstructured":"Herskowitz, J. H. et al. Asparaginyl endopeptidase cleaves TDP-43 in brain. Proteomics 12, 2455\u20132463 (2012).","journal-title":"Proteomics"},{"key":"494_CR37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jnen\/60.1.94","volume":"60","author":"E Levy","year":"2001","unstructured":"Levy, E. et al. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J. Neuropathol. Exp. Neurol. 60, 94\u2013104 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"494_CR38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fnmol.2012.00079","volume":"5","author":"G Kaur","year":"2012","unstructured":"Kaur, G. & Levy, E. Cystatin C in Alzheimer\u2019s disease. Front Mol. Neurosci. 5, 79 (2012).","journal-title":"Front Mol. Neurosci."},{"key":"494_CR39","volume":"6","author":"Z Zhang","year":"2015","unstructured":"Zhang, Z. et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer\u2019s disease. Nat. Commun. 6, 8762 (2015).","journal-title":"Nat. Commun."},{"key":"494_CR40","doi-asserted-by":"publisher","unstructured":"Zhang, Z. et al. delta-Secretase-cleaved Tau stimulates Abeta production via upregulating STAT1-BACE1 signaling in Alzheimer\u2019s disease. Mol Psychiatry https:\/\/doi.org\/10.1038\/s41380-018-0286-z. (2018).","DOI":"10.1038\/s41380-018-0286-z"},{"key":"494_CR41","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer\u2019s disease. Nat. Commun. 8, 14740 (2017).","journal-title":"Nat. Commun."},{"key":"494_CR42","doi-asserted-by":"crossref","first-page":"24512","DOI":"10.1074\/jbc.M109.026237","volume":"284","author":"SW Jang","year":"2009","unstructured":"Jang, S. W. et al. Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J. Biol. Chem. 284, 24512\u201324525 (2009).","journal-title":"J. Biol. Chem."},{"key":"494_CR43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.molcel.2017.07.018","volume":"67","author":"ZH Wang","year":"2017","unstructured":"Wang, Z. H. et al. Delta-secretase phosphorylation by SRPK2 enhances its enzymatic activity, provoking pathogenesis in Alzheimer\u2019s disease. Mol. Cell 67, 812\u2013825 e815 (2017).","journal-title":"Mol. Cell"},{"key":"494_CR44","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1084\/jem.20180539","volume":"215","author":"ZH Wang","year":"2018","unstructured":"Wang, Z. H. et al. Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies. J. Exp. Med 215, 3038\u20133056 (2018).","journal-title":"J. Exp. Med"},{"key":"494_CR45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00005072-199907000-00007","volume":"58","author":"I Ferrer","year":"1999","unstructured":"Ferrer, I. et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 58, 729\u2013739 (1999).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"494_CR46","doi-asserted-by":"crossref","first-page":"e99007","DOI":"10.1172\/jci.insight.99007","volume":"3","author":"ZH Wang","year":"2018","unstructured":"Wang, Z. H. et al. BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT. JCI Insight 3, e99007 (2018).","journal-title":"JCI Insight"},{"key":"494_CR47","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1073\/pnas.1901348116","volume":"116","author":"J Xiang","year":"2019","unstructured":"Xiang, J. et al. Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer\u2019s disease pathologies. Proc. Natl. Acad. Sci. USA 116, 9094\u20139102 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"494_CR48","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1523\/JNEUROSCI.4236-05.2006","volume":"26","author":"MT Heneka","year":"2006","unstructured":"Heneka, M. T. et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343\u20131354 (2006).","journal-title":"J. Neurosci."},{"key":"494_CR49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.biopsych.2012.06.013","volume":"73","author":"T Hammerschmidt","year":"2013","unstructured":"Hammerschmidt, T. et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP\/PS1 mice. Biol. Psychiatry 73, 454\u2013463 (2013).","journal-title":"Biol. Psychiatry"},{"key":"494_CR50","volume":"9","author":"ZH Wang","year":"2018","unstructured":"Wang, Z. H. et al. C\/EBPbeta regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer\u2019s disease. Nat. Commun. 9, 1784 (2018).","journal-title":"Nat. Commun."},{"key":"494_CR51","doi-asserted-by":"crossref","first-page":"E12427","DOI":"10.1073\/pnas.1815915115","volume":"115","author":"H Wang","year":"2018","unstructured":"Wang, H., Liu, X., Chen, S. & Ye, K. Spatiotemporal activation of the C\/EBPbeta\/delta-secretase axis regulates the pathogenesis of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 115, E12427\u2013E12434 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.celrep.2019.06.054","volume":"28","author":"ZH Wang","year":"2019","unstructured":"Wang, Z. H. et al. Deficiency in BDNF\/TrkB neurotrophic activity stimulates delta-secretase by upregulating C\/EBPbeta in Alzheimer\u2019s disease. Cell Rep. 28, 655\u2013669 e655 (2019).","journal-title":"Cell Rep."},{"key":"494_CR53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/0929867013372922","volume":"8","author":"LM Sayre","year":"2001","unstructured":"Sayre, L. M., Smith, M. A. & Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med Chem. 8, 721\u2013738 (2001).","journal-title":"Curr. Med Chem."},{"key":"494_CR54","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/0006-2952(87)90135-3","volume":"36","author":"JF Towell 3rd","year":"1987","unstructured":"Towell, J. F. 3rd & Wang, R. I. Hydrogen peroxide-induced glutathione depletion and aldehyde dehydrogenase inhibition in erythrocytes. Biochem Pharm. 36, 2087\u20132093 (1987).","journal-title":"Biochem Pharm."},{"key":"494_CR55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0197-4580(97)00108-5","volume":"18","author":"MA Lovell","year":"1997","unstructured":"Lovell, M. A., Ehmann, W. D., Mattson, M. P. & Markesbery, W. R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer\u2019s disease. Neurobiol. Aging 18, 457\u2013461 (1997).","journal-title":"Neurobiol. Aging"},{"key":"494_CR56","doi-asserted-by":"crossref","first-page":"18344","DOI":"10.1074\/jbc.M000206200","volume":"275","author":"JM Souza","year":"2000","unstructured":"Souza, J. M., Giasson, B. I., Chen, Q., Lee, V. M. & Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344\u201318349 (2000).","journal-title":"J. Biol. Chem."},{"issue":"Suppl 3","key":"494_CR57","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner, P. Oxidative stress in Parkinson\u2019s disease. Ann. Neurol. 53(Suppl 3), S26\u2013S36 (2003). discussion S36-28.","journal-title":"Ann. Neurol."},{"key":"494_CR58","doi-asserted-by":"crossref","first-page":"e98878","DOI":"10.15252\/embj.201798878","volume":"37","author":"SS Kang","year":"2018","unstructured":"Kang, S. S. et al. alpha-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson\u2019s disease. EMBO J. 37, e98878 (2018).","journal-title":"EMBO J."},{"key":"494_CR59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nsmb.3433","volume":"24","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson\u2019s disease. Nat. Struct. Mol. Biol. 24, 632\u2013642 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"494_CR60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0006-8993(96)00129-1","volume":"722","author":"WJ Burke","year":"1996","unstructured":"Burke, W. J., Schmitt, C. A., Gillespie, K. N. & Li, S. W. Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res. 722, 232\u2013235 (1996).","journal-title":"Brain Res"},{"key":"494_CR61","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0006-8993(98)01211-6","volume":"816","author":"WJ Burke","year":"1999","unstructured":"Burke, W. J. et al. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer\u2019s disease: mechanism of neuron death. Brain Res. 816, 633\u2013637 (1999).","journal-title":"Brain Res."},{"key":"494_CR62","doi-asserted-by":"crossref","first-page":"24468","DOI":"10.1074\/jbc.270.41.24468","volume":"270","author":"LV Favreau","year":"1995","unstructured":"Favreau, L. V. & Pickett, C. B. The rat quinone reductase antioxidant response element. Identification of the nucleotide sequence required for basal and inducible activity and detection of antioxidant response element-binding proteins in hepatoma and non-hepatoma cell lines. J. Biol. Chem. 270, 24468\u201324474 (1995).","journal-title":"J. Biol. Chem."},{"key":"494_CR63","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.freeradbiomed.2011.10.453","volume":"52","author":"Y Hou","year":"2012","unstructured":"Hou, Y. et al. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT\/enhancer-binding protein beta during adipogenesis. Free Radic. Biol. Med. 52, 462\u2013472 (2012).","journal-title":"Free Radic. Biol. Med."},{"key":"494_CR64","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-8-156","volume":"8","author":"M Straccia","year":"2011","unstructured":"Straccia, M. et al. Pro-inflammatory gene expression and neurotoxic effects of activated microglia are attenuated by absence of CCAAT\/enhancer binding protein beta. J. Neuroinflammation 8, 156 (2011).","journal-title":"J. Neuroinflammation"},{"key":"494_CR65","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/j.1460-2075.1990.tb08316.x","volume":"9","author":"S Akira","year":"1990","unstructured":"Akira, S. et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C\/EBP family. EMBO J. 9, 1897\u20131906 (1990).","journal-title":"EMBO J."},{"key":"494_CR66","doi-asserted-by":"crossref","first-page":"e9516","DOI":"10.1371\/journal.pone.0009516","volume":"5","author":"O Meir","year":"2010","unstructured":"Meir, O., Dvash, E., Werman, A. & Rubinstein, M. C\/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models. PLoS ONE 5, e9516 (2010).","journal-title":"PLoS ONE"},{"key":"494_CR67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jcp.10116","volume":"192","author":"ES Hungness","year":"2002","unstructured":"Hungness, E. S. et al. Transcription factors C\/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes. J. Cell Physiol. 192, 64\u201370 (2002).","journal-title":"J. Cell Physiol."},{"key":"494_CR68","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1172\/JCI130513","volume":"130","author":"SS Kang","year":"2020","unstructured":"Kang, S. S. et al. Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. J. Clin. Invest. 130, 422\u2013437 (2020).","journal-title":"J. Clin. Invest"},{"key":"494_CR69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00213-005-0139-8","volume":"183","author":"BN Bourdelat-Parks","year":"2005","unstructured":"Bourdelat-Parks, B. N. et al. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacol. (Berl.) 183, 72\u201380 (2005).","journal-title":"Psychopharmacol. (Berl.)"},{"key":"494_CR70","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1073\/pnas.1310025111","volume":"111","author":"EM Vazey","year":"2014","unstructured":"Vazey, E. M. & Aston-Jones, G. Designer receptor manipulations reveal a role of the locus coeruleus noradrenergic system in isoflurane general anesthesia. Proc. Natl Acad. Sci. USA 111, 3859\u20133864 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuron.2016.01.026","volume":"89","author":"DW Sanders","year":"2016","unstructured":"Sanders, D. W., Kaufman, S. K., Holmes, B. B. & Diamond, M. I. Prions and protein assemblies that convey biological information in health and disease. Neuron 89, 433\u2013448 (2016).","journal-title":"Neuron"},{"key":"494_CR72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00401-015-1458-4","volume":"130","author":"M Iba","year":"2015","unstructured":"Iba, M. et al. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC\u2019s afferent and efferent connections. Acta Neuropathol. 130, 349\u2013362 (2015).","journal-title":"Acta Neuropathol."},{"key":"494_CR73","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","volume":"82","author":"DW Sanders","year":"2014","unstructured":"Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271\u20131288 (2014).","journal-title":"Neuron"},{"key":"494_CR74","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1073\/pnas.1301175110","volume":"110","author":"F Clavaguera","year":"2013","unstructured":"Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535\u20139540 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR75","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1084\/jem.20160833","volume":"213","author":"JL Guo","year":"2016","unstructured":"Guo, J. L. et al. Unique pathological tau conformers from Alzheimer\u2019s brains transmit tau pathology in nontransgenic mice. J. Exp. Med 213, 2635\u20132654 (2016).","journal-title":"J. Exp. Med"},{"key":"494_CR76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","volume":"92","author":"SK Kaufman","year":"2016","unstructured":"Kaufman, S. K. et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92, 796\u2013812 (2016).","journal-title":"Neuron"},{"key":"494_CR77","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584\u20131593 (2015).","journal-title":"Nat. Neurosci."},{"key":"494_CR78","doi-asserted-by":"crossref","first-page":"104518","DOI":"10.1016\/j.nbd.2019.104518","volume":"130","author":"A Behrendt","year":"2019","unstructured":"Behrendt, A. et al. Asparagine endopeptidase cleaves tau at N167 after uptake into microglia. Neurobiol. Dis. 130, 104518 (2019).","journal-title":"Neurobiol. Dis."},{"key":"494_CR79","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy, A. et al. Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur. J. Nucl. Med Mol. Imaging 46, 1276\u20131286 (2019).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"494_CR80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow, K. et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys Abeta(1-42), pTau and tTau CSF immunoassays. Sci. Rep. 9, 19024 (2019).","journal-title":"Sci. Rep."},{"key":"494_CR81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41422-019-0241-9","volume":"30","author":"EH Ahn","year":"2020","unstructured":"Ahn, E. H. et al. Initiation of Parkinson\u2019s disease from gut to brain by delta-secretase. Cell Res 30, 70\u201387 (2020).","journal-title":"Cell Res"},{"key":"494_CR82","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","volume":"90","author":"K Ueda","year":"1993","unstructured":"Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282\u201311286 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR83","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00401-003-0750-x","volume":"106","author":"Y Wakisaka","year":"2003","unstructured":"Wakisaka, Y. et al. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 106, 374\u2013382 (2003).","journal-title":"Acta Neuropathol."},{"key":"494_CR84","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah, E. et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc. Natl Acad. Sci. USA 98, 12245\u201312250 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR85","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/jnr.21352","volume":"85","author":"T Kurata","year":"2007","unstructured":"Kurata, T. et al. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. J. Neurosci. Res. 85, 2246\u20132252 (2007).","journal-title":"J. Neurosci. Res."},{"key":"494_CR86","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"494_CR87","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med"},{"key":"494_CR88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24\u201326 (2006).","journal-title":"Nat. Genet"},{"key":"494_CR89","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106\u2013118 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"494_CR90","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","volume":"108","author":"M Jin","year":"2011","unstructured":"Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819\u20135824 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"494_CR91","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005072-199904000-00008","volume":"58","author":"DG Davis","year":"1999","unstructured":"Davis, D. G., Schmitt, F. A., Wekstein, D. R. & Markesbery, W. R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58, 376\u2013388 (1999).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"494_CR92","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe, C. C. et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718\u20131725 (2007).","journal-title":"Neurology"},{"key":"494_CR93","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698\u2013712 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"494_CR94","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.nbd.2005.05.027","volume":"20","author":"EM Ribe","year":"2005","unstructured":"Ribe, E. M. et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP\/tau transgenic mice. Neurobiol. Dis. 20, 814\u2013822 (2005).","journal-title":"Neurobiol. Dis."},{"key":"494_CR95","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","volume":"36","author":"J Bright","year":"2015","unstructured":"Bright, J. et al. Human secreted tau increases amyloid-beta production. Neurobiol. Aging 36, 693\u2013709 (2015).","journal-title":"Neurobiol. Aging"},{"key":"494_CR96","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1471-4159.2004.02737.x","volume":"91","author":"O Wirths","year":"2004","unstructured":"Wirths, O., Multhaup, G. & Bayer, T. A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem 91, 513\u2013520 (2004).","journal-title":"J. Neurochem"},{"key":"494_CR97","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/hmg\/3.4.569","volume":"3","author":"MC Chartier-Harlin","year":"1994","unstructured":"Chartier-Harlin, M. C. et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer\u2019s disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3, 569\u2013574 (1994).","journal-title":"Hum. Mol. Genet"},{"key":"494_CR98","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).","journal-title":"Sci. Transl. Med."},{"key":"494_CR99","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"494_CR100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0197-0186(92)90066-Z","volume":"21","author":"G Eisenhofer","year":"1992","unstructured":"Eisenhofer, G., Smolich, J. J. & Esler, M. D. Increased cardiac production of dihydroxyphenylalanine (DOPA) during sympathetic stimulation in anaesthetized dogs. Neurochem. Int. 21, 37\u201344 (1992).","journal-title":"Neurochem. Int"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00494-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00494-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:32:36Z","timestamp":1696595556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-020-00494-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1038\/s12276-020-00494-7","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}